strong>Cleveland Biolabs Inc., of Buffalo, N.Y., reported that a phase I study of CBLB612, a drug in development for oncology indications, including the prevention of chemotherapy-induced myelosuppression, showed that single subcutaneous injections of the drug were generally well tolerated in 56 healthy volunteers.